Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: pathophysiologic foundation and clinical findings.

Journal Article (Journal Article;Review)

The pathophysiologic basis for potent platelet inhibition in the acute coronary syndromes has been established. In the setting of PTCA for unstable angina and non-Q-wave myocardial infarction, there are clear data for a benefit of GP IIb/IIIa inhibition, whereas for primary PTCA in evolving myocardial infarction, preliminary data are very encouraging and a large-scale clinical trial is nearly completed. Glycoprotein IIb/IIIa inhibition as an adjunct to medical therapy for unstable angina is also the subject of encouraging preliminary data, and 3 large-scale clinical trials have just been completed. Preliminary data have also been accrued for GP IIb/IIIa inhibition as conjunctive therapy with thrombolytic agents, and large clinical trials are now commencing.

Full Text

Duke Authors

Cited Authors

  • Kleiman, NS; Lincoff, AM; Ohman, EM; Harrington, RA

Published Date

  • October 1998

Published In

Volume / Issue

  • 136 / 4 Pt 2 Su

Start / End Page

  • S32 - S42

PubMed ID

  • 9778086

International Standard Serial Number (ISSN)

  • 0002-8703

Digital Object Identifier (DOI)

  • 10.1053/hj.1998.v136.93434


  • eng

Conference Location

  • United States